Wedbush Predicts Stronger Earnings for Werewolf Therapeutics

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Investment analysts at Wedbush upped their FY2025 earnings estimates for shares of Werewolf Therapeutics in a research note issued on Tuesday, November 4th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($1.54) per share for the year, up from their prior estimate of ($1.66). The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics’ Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.64) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.74) EPS.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03.

Several other research firms also recently weighed in on HOWL. JMP Securities lowered their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Bank of America dropped their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Werewolf Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $1.20 on Friday. The company has a market capitalization of $58.25 million, a price-to-earnings ratio of -0.74 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 5.30. Werewolf Therapeutics has a 1-year low of $0.60 and a 1-year high of $2.41. The business has a 50 day moving average of $1.61 and a 200 day moving average of $1.32.

Insider Transactions at Werewolf Therapeutics

In other news, major shareholder Ansbert Gadicke sold 140,488 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the transaction, the insider owned 6,007,122 shares in the company, valued at approximately $7,328,688.84. This represents a 2.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Luke Evnin sold 90,164 shares of the stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $110,000.08. Following the sale, the director owned 3,853,195 shares in the company, valued at approximately $4,700,897.90. This represents a 2.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,150,286 shares of company stock valued at $2,995,317 in the last quarter. 23.60% of the stock is owned by insiders.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Vontobel Holding Ltd. purchased a new stake in Werewolf Therapeutics in the 1st quarter worth $34,000. Charles Schwab Investment Management Inc. raised its stake in Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after purchasing an additional 23,852 shares during the period. MPM Asset Management LLC lifted its holdings in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. Nuveen LLC bought a new position in Werewolf Therapeutics in the 1st quarter worth approximately $71,000. Finally, MPM Bioimpact LLC raised its position in shares of Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after buying an additional 20,799 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.